AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 63 min read$NTRA

Chapman Steven Leonard sold $380K of NTRA

Chapman Steven Leonard (CEO AND PRESIDENT) sold 1,742 shares of Natera, Inc. (NTRA) at $218.28 ($0.38M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chapman Steven Leonard
Published Jun 6, 2026, 1:05 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 6, 2026, 1:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The main tradable element is sentiment/positioning around insider activity; there is no new company-specific fundamental information in the filing.

02

Market read

Traders may briefly reassess sentiment/technical positioning, but the 10b5-1 designation limits fundamental interpretation.

03

What to watch

The disclosure does not reveal intent beyond the pre-arranged plan; without accompanying buys, it’s hard to infer directional conviction.

Relevance 6/10Novelty 4/10Timing: After-hours/next-session read-through of an SEC Form 4 insider sale (filed 2026-06-05).

Background

This is an SEC Form 4 insider transaction for Natera, reporting an officer/director open-market sale executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera CEO and president Chapman Steven Leonard sold $380.3K of NTRA shares via an open-market transaction under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely sentiment-driven and short-lived.

Evidence & confidence

The filing is a routine insider transaction disclosure and explicitly notes a pre-arranged 10b5-1 plan, reducing interpretive weight versus discretionary selling.

Market effects

Sector

Minimal; single-company insider sale without new operational/regulatory/clinical catalysts.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

10b5-1 sales can coincide with diversification or liquidity needs and may not reflect bearish expectations; the market may overreact to the headline.

Key entities

  • issuer
    Natera, Inc.

    US-listed company whose CEO/president reported an open-market share sale under a 10b5-1 plan.

  • insider
    Chapman Steven Leonard

    CEO and president who sold 1,742 shares at ~$218.28/share.

Read at source← All news

Related articles

AUG 7
$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.

stockstotrade.com6 min
AUG 7
$NTRAMedAI 8/10

NTRA Soars As Natera Beats Q2 And Lifts 2026 Outlook

Natera (NTRA) shares rose about 21% after the company reported Q2 2026 revenue of $752.8M versus ~$661.2M consensus and a $0.47 per-share loss versus a ~$0.49 loss estimate. Natera lifted FY2026 revenue guidance to $2.85B to $2.91B. The article cites gross margin around 65% and notes free cash flow about $18M.

timothysykes.com6 min
AUG 7
$NTRAHighAI 9/10

NTRA Stock Soars After Earnings Beat And Raised 2026 Outlook

Natera Inc. (NTRA) shares rose after Q2 results and a raised 2026 outlook. According to the company, Q2 revenue was $752.8M vs $661.2M consensus, with a Q2 loss of $0.47 per share vs $0.49 expected. Full-year 2026 revenue guidance was lifted to $2.85B–$2.91B. The company also submitted its Signatera MRD test to Japan’s PMDA for muscle-invasive bladder cancer.

stockstotrade.com6 min
AUG 7
$NTRAMedAI 8/10

Natera Stock Hits 52-Week High - Here's Why - Natera (NASDAQ:NTRA)

Natera (NTRA) reported Q2 adjusted loss of 47 cents per share, better than the 51-cent consensus. Revenue rose 37.7% to $752.8M, above $660.7M estimates, driven by higher test volumes and improved pricing. Oncology tests grew 56% YoY and the company processed 1.04M tests. Fiscal 2026 revenue guidance was raised to $2.85B-$2.91B. Analysts lifted price targets; shares hit a 52-week high.

benzinga.com4 min
AUG 7
$NTRAMedAI 8/10

These Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Months

Natera (NTRA) shares hit fresh 52-week highs after Q2 revenue of $752.8M beat estimates of $661.3M and the company raised FY2026 revenue guidance to $2.85B-$2.91B. BTIG lifted its NTRA price target to $320 and JPMorgan to $360. Halozyme (HALO) also reached a 52-week high after Q2 revenue rose 48% to $481M; Leerink upgraded to Outperform and set $110.

newsable.asianetnews.com6 min